{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T19:05:35Z","timestamp":1788807935383,"version":"build-2803163510"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,12]]},"DOI":"10.7759\/cureus.110720","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T09:38:36Z","timestamp":1781257116000},"source":"Crossref","is-referenced-by-count":1,"title":["Visual and Neuro-Ophthalmic Manifestations of John Cunningham (JC) Virus-Related Natalizumab-Associated Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Tornike","family":"Jangirashvili","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orchid","family":"Parthiv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lolita","family":"Shengelia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zurab","family":"Tabeshadze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Kontchoshvili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher A","family":"Waked","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ribal M","family":"Tamer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren G","year":"2012","unstructured":"Bloomgren G, Richman S, Hotermans C, et al.. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012, 366:1870-80. 10.1056\/NEJMoa1107829","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-020-00427-y","article-title":"Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease","volume":"17","author":"Cortese I","year":"2021","unstructured":"Cortese I, Reich DS, Nath A. Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease. Nat Rev Neurol. 2021, 17:37-51. 10.1038\/s41582-020-00427-y","journal-title":"Nat Rev Neurol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ddmod.2020.02.002","article-title":"Natalizumab related progressive multifocal leukoencephalopathy","volume":"32","author":"Zhovtis Ryerson L","year":"2020","unstructured":"Zhovtis Ryerson L, Major EO. Natalizumab related progressive multifocal leukoencephalopathy. Drug Discov Today Dis Models. 2020, 32:13-9. 10.1016\/j.ddmod.2020.02.002","journal-title":"Drug Discov Today Dis Models"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2021.577721","article-title":"Disease-modifying therapies and progressive multifocal leukoencephalopathy in multiple sclerosis: a systematic review and meta-analysis","volume":"360","author":"Sriwastava S","year":"2021","unstructured":"Sriwastava S, Kataria S, Srivastava S, et al.. Disease-modifying therapies and progressive multifocal leukoencephalopathy in multiple sclerosis: a systematic review and meta-analysis. J Neuroimmunol. 2021, 360:577721. 10.1016\/j.jneuroim.2021.577721","journal-title":"J Neuroimmunol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2022.120459","article-title":"Progressive multifocal leukoencephalopathy in anti-CD20 and other monoclonal antibody (mAb) therapies used in multiple sclerosis: A review","volume":"443","author":"Sharma K","year":"2022","unstructured":"Sharma K, Tolaymat S, Yu H, et al.. Progressive multifocal leukoencephalopathy in anti-CD20 and other monoclonal antibody (mAb) therapies used in multiple sclerosis: A review. J Neurol Sci. 2022, 443:120459. 10.1016\/j.jns.2022.120459","journal-title":"J Neurol Sci"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24286","article-title":"Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"76","author":"Plavina T","year":"2014","unstructured":"Plavina T, Subramanyam M, Bloomgren G, et al.. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol. 2014, 76:802-12. 10.1002\/ana.24286","journal-title":"Ann Neurol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/WNO.0000000000000271","article-title":"Progressive multifocal leukoencephalopathy: recent advances and a neuro-ophthalmological review","volume":"35","author":"Sudhakar P","year":"2015","unstructured":"Sudhakar P, Bachman DM, Mark AS, Berger JR, Kedar S. Progressive multifocal leukoencephalopathy: recent advances and a neuro-ophthalmological review. J Neuroophthalmol. 2015, 35:296-305. 10.1097\/WNO.0000000000000271","journal-title":"J Neuroophthalmol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2015-311411","article-title":"MRI characteristics of early PML-IRIS after natalizumab treatment in patients with MS","volume":"87","author":"Wattjes MP","year":"2016","unstructured":"Wattjes MP, Wijburg MT, Vennegoor A, et al.. MRI characteristics of early PML-IRIS after natalizumab treatment in patients with MS. J Neurol Neurosurg Psychiatry. 2016, 87:879-84. 10.1136\/jnnp-2015-311411","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awab419","article-title":"The neuroradiology of progressive multifocal leukoencephalopathy: a clinical trial perspective","volume":"145","author":"Baldassari LE","year":"2022","unstructured":"Baldassari LE, Wattjes MP, Cortese IC, et al.. The neuroradiology of progressive multifocal leukoencephalopathy: a clinical trial perspective. Brain. 2022, 145:426-40. 10.1093\/brain\/awab419","journal-title":"Brain"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30282-X","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies","volume":"16","author":"Ho PR","year":"2017","unstructured":"Ho PR, Koendgen H, Campbell N. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies. Lancet Neurol. 2017, 16:925-33. 10.1016\/S1474-4422(17)30282-X","journal-title":"Lancet Neurol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0168376","article-title":"Natalizumab-related progressive multifocal leukoencephalopathy in multiple sclerosis: findings from an Italian independent registry","volume":"11","author":"Prosperini L","year":"2016","unstructured":"Prosperini L, de Rossi N, Scarpazza C, Moiola L, Cosottini M, Gerevini S, Capra R. Natalizumab-related progressive multifocal leukoencephalopathy in multiple sclerosis: findings from an Italian independent registry. PLoS One. 2016, 11:e0168376. 10.1371\/journal.pone.0168376","journal-title":"PLoS One"},{"key":"ref12","doi-asserted-by":"crossref","DOI":"10.1007\/s00415-023-11924-7","article-title":"Long-term outcome of natalizumab-associated progressive multifocal leukoencephalopathy in Austria: a nationwide retrospective study","volume":"271","author":"Moser T","year":"2024","unstructured":"Moser T, Zimmermann G, Baumgartner A. Long-term outcome of natalizumab-associated progressive multifocal leukoencephalopathy in Austria: a nationwide retrospective study. J Neurol. 2024, 271:374-85.","journal-title":"J Neurol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007451","article-title":"Natalizumab-associated progressive multifocal leukoencephalopathy in Germany","volume":"92","author":"Blankenbach K","year":"2019","unstructured":"Blankenbach K, Schwab N, Hofner B, Adams O, Keller-Stanislawski B, Warnke C. Natalizumab-associated progressive multifocal leukoencephalopathy in Germany. Neurology. 2019, 92:e2232-9. 10.1212\/WNL.0000000000007451","journal-title":"Neurology"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000618","article-title":"Progressive multifocal leukoencephalopathy: a 25-year retrospective cohort study","volume":"6","author":"Anand P","year":"2019","unstructured":"Anand P, Hotan GC, Vogel A, Venna N, Mateen FJ. Progressive multifocal leukoencephalopathy: a 25-year retrospective cohort study. Neurol Neuroimmunol Neuroinflamm. 2019, 6:618. 10.1212\/NXI.0000000000000618","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S30636","article-title":"Hemianopia and visual loss due to progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis","volume":"6","author":"Herold TR","year":"2012","unstructured":"Herold TR, Jakl V, Graser A, Eibl-Lindner K. Hemianopia and visual loss due to progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis. Clin Ophthalmol. 2012, 6:1131-3. 10.2147\/OPTH.S30636","journal-title":"Clin Ophthalmol"},{"key":"ref16","article-title":"PML under natalizumab treatment","volume":"480","author":"Aygun E","year":"2025","unstructured":"Aygun E, Sen S, Terzi M. PML under natalizumab treatment. J Neurol Sci. 2025, 480:124807.","journal-title":"J Neurol Sci"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1186\/s41983-020-00260-6","article-title":"Natalizumab-associated progressive multifocal leukoencephalopathy (PML) in multiple sclerosis (MS): \"a case report from Ireland with review of literature, clinical pitfalls and future direction\"","volume":"57","author":"Mansoor S","year":"2021","unstructured":"Mansoor S, Mullane G, Adenan MH, Kelly S, Water A, McPartland G, Murphy K. Natalizumab-associated progressive multifocal leukoencephalopathy (PML) in multiple sclerosis (MS): \"a case report from Ireland with review of literature, clinical pitfalls and future direction\". Egypt J Neurol Psychiatr Neurosurg. 2021, 57:7. 10.1186\/s41983-020-00260-6","journal-title":"Egypt J Neurol Psychiatr Neurosurg"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104830","article-title":"Radiological abnormalities in progressive multifocal leukoencephalopathy: identifying typical and atypical imaging patterns for early diagnosis and differential considerations","volume":"77","author":"Soni N","year":"2023","unstructured":"Soni N, Ora M, Mangla R, et al.. Radiological abnormalities in progressive multifocal leukoencephalopathy: identifying typical and atypical imaging patterns for early diagnosis and differential considerations. Mult Scler Relat Disord. 2023, 77:104830. 10.1016\/j.msard.2023.104830","journal-title":"Mult Scler Relat Disord"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000346","article-title":"Natalizumab-PML survivors with subsequent MS treatment: clinico-radiologic outcome","volume":"4","author":"Maillart E","year":"2017","unstructured":"Maillart E, Vidal JS, Brassat D, et al.. Natalizumab-PML survivors with subsequent MS treatment: clinico-radiologic outcome. Neurol Neuroimmunol Neuroinflamm. 2017, 4:e346. 10.1212\/NXI.0000000000000346","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0176415","article-title":"Metabolic profiles by 1H-magnetic resonance spectroscopy in natalizumab-associated post-PML lesions of multiple sclerosis patients who survived progressive multifocal leukoencephalopathy (PML)","volume":"12","author":"Schneider R","year":"2017","unstructured":"Schneider R, Bellenberg B, Hoepner R, et al.. Metabolic profiles by 1H-magnetic resonance spectroscopy in natalizumab-associated post-PML lesions of multiple sclerosis patients who survived progressive multifocal leukoencephalopathy (PML). PLoS One. 2017, 12:e0176415. 10.1371\/journal.pone.0176415","journal-title":"PLoS One"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/809252","article-title":"Neuroimaging of natalizumab complications in multiple sclerosis: PML and other associated entities","volume":"2015","author":"Honce JM","year":"2015","unstructured":"Honce JM, Nagae L, Nyberg E. Neuroimaging of natalizumab complications in multiple sclerosis: PML and other associated entities. Mult Scler Int. 2015, 2015:809252. 10.1155\/2015\/809252","journal-title":"Mult Scler Int"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/neup.12562","article-title":"Development of demyelinating lesions in progressive multifocal leukoencephalopathy (PML): Comparison of magnetic resonance images and neuropathology of post-mortem brain","volume":"39","author":"Ono D","year":"2019","unstructured":"Ono D, Shishido-Hara Y, Mizutani S, et al.. Development of demyelinating lesions in progressive multifocal leukoencephalopathy (PML): Comparison of magnetic resonance images and neuropathology of post-mortem brain. Neuropathology. 2019, 39:294-306. 10.1111\/neup.12562","journal-title":"Neuropathology"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002586","article-title":"Punctate pattern: A promising imaging marker for the diagnosis of natalizumab-associated PML","volume":"86","author":"Hodel J","year":"2016","unstructured":"Hodel J, Darchis C, Outteryck O, et al.. Punctate pattern: A promising imaging marker for the diagnosis of natalizumab-associated PML. Neurology. 2016, 86:1516-23. 10.1212\/WNL.0000000000002586","journal-title":"Neurology"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2025.1575653","article-title":"Natalizumab-associated progressive multifocal leukoencephalopathy","volume":"16","author":"Glenn T","year":"2025","unstructured":"Glenn T, Berger JR, McEntire CR. Natalizumab-associated progressive multifocal leukoencephalopathy. Front Neurol. 2025, 16:1575653. 10.3389\/fneur.2025.1575653","journal-title":"Front Neurol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2014-308630","article-title":"MRI pattern in asymptomatic natalizumab-associated PML","volume":"86","author":"Wattjes MP","year":"2015","unstructured":"Wattjes MP, Vennegoor A, Steenwijk MD, et al.. MRI pattern in asymptomatic natalizumab-associated PML. J Neurol Neurosurg Psychiatry. 2015, 86:793-8. 10.1136\/jnnp-2014-308630","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2018.0094","article-title":"Association of progressive multifocal leukoencephalopathy lesion volume with JC virus polymerase chain reaction results in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis","volume":"75","author":"Wijburg MT","year":"2018","unstructured":"Wijburg MT, Kleerekooper I, Lissenberg-Witte BI, et al.. Association of progressive multifocal leukoencephalopathy lesion volume with JC virus polymerase chain reaction results in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. JAMA Neurol. 2018, 75:827-33. 10.1001\/jamaneurol.2018.0094","journal-title":"JAMA Neurol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2016-313772","article-title":"MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance","volume":"87","author":"Wijburg MT","year":"2016","unstructured":"Wijburg MT, Witte BI, Vennegoor A, et al.. MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance. J Neurol Neurosurg Psychiatry. 2016, 87:1138-45. 10.1136\/jnnp-2016-313772","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24153","article-title":"Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"76","author":"Warnke C","year":"2014","unstructured":"Warnke C, von Geldern G, Markwerth P, et al.. Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol. 2014, 76:792-801. 10.1002\/ana.24153","journal-title":"Ann Neurol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2018-319208","article-title":"Early diagnosis of progressive multifocal leucoencephalopathy: longitudinal lesion evolution","volume":"90","author":"Scarpazza C","year":"2019","unstructured":"Scarpazza C, Signori A, Prosperini L, Sormani MP, Cosottini M, Capra R, Gerevini S. Early diagnosis of progressive multifocal leucoencephalopathy: longitudinal lesion evolution. J Neurol Neurosurg Psychiatry. 2019, 90:261-7. 10.1136\/jnnp-2018-319208","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318268465b","article-title":"Metabolic profile of PML lesions in patients with and without IRIS: an observational study","volume":"79","author":"Gheuens S","year":"2012","unstructured":"Gheuens S, Ngo L, Wang X, Alsop DC, Lenkinski RE, Koralnik IJ. Metabolic profile of PML lesions in patients with and without IRIS: an observational study. Neurology. 2012, 79:1041-8. 10.1212\/WNL.0b013e318268465b","journal-title":"Neurology"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-011-0900-5","article-title":"Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy","volume":"123","author":"Metz I","year":"2012","unstructured":"Metz I, Radue EW, Oterino A, et al.. Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy. Acta Neuropathol. 2012, 123:235-45. 10.1007\/s00401-011-0900-5","journal-title":"Acta Neuropathol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1097\/NEN.0b013e31825caf2c","article-title":"Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab","volume":"71","author":"Kleinschmidt-DeMasters BK","year":"2012","unstructured":"Kleinschmidt-DeMasters BK, Miravalle A, Schowinsky J, Corboy J, Vollmer T. Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab. J Neuropathol Exp Neurol. 2012, 71:604-17. 10.1097\/NEN.0b013e31825caf2c","journal-title":"J Neuropathol Exp Neurol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awab179","article-title":"Giant axonal neuropathy: cross-sectional analysis of a large natural history cohort","volume":"144","author":"Bharucha-Goebel DX","year":"2021","unstructured":"Bharucha-Goebel DX, Norato G, Saade D, et al.. Giant axonal neuropathy: cross-sectional analysis of a large natural history cohort. Brain. 2021, 144:3239-50. 10.1093\/brain\/awab179","journal-title":"Brain"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.114","article-title":"Outcome and survival of asymptomatic PML in natalizumab-treated MS patients","volume":"1","author":"Dong-Si T","year":"2014","unstructured":"Dong-Si T, Richman S, Wattjes MP, et al.. Outcome and survival of asymptomatic PML in natalizumab-treated MS patients. Ann Clin Transl Neurol. 2014, 1:755-64. 10.1002\/acn3.114","journal-title":"Ann Clin Transl Neurol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1007\/s13365-015-0316-4","article-title":"Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy","volume":"21","author":"Dong-Si T","year":"2015","unstructured":"Dong-Si T, Gheuens S, Gangadharan A, et al.. Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy. J Neurovirol. 2015, 21:637-44. 10.1007\/s13365-015-0316-4","journal-title":"J Neurovirol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/502268-visual-and-neuro-ophthalmic-manifestations-of-john-cunningham-jc-virus-related-natalizumab-associated-progressive-multifocal-leukoencephalopathy-in-multiple-sclerosis-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T09:38:40Z","timestamp":1781257120000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/502268-visual-and-neuro-ophthalmic-manifestations-of-john-cunningham-jc-virus-related-natalizumab-associated-progressive-multifocal-leukoencephalopathy-in-multiple-sclerosis-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":35,"URL":"https:\/\/doi.org\/10.7759\/cureus.110720","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,12]]}}}